Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T15:03:17.071Z.
Calculation as of: 2026-10-06T15:03:17.071Z.
Quote observation: 2026-10-06T15:00:33.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7de7752a9f7c92cf302168b3adc2b8952dbd3ee015c15fa7e623ade4200d4f53
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$838.73M
EV/Sales Ratio
109.69x
TTM Avg
171.82x
3Y Avg
125.82x
5Y Avg
125.82x
Market Cap
$835.48M
EV/Sales Ratio
6.70x
TTM Avg
7.73x
3Y Avg
8.84x
5Y Avg
8.84x
Market Cap
$857.04M
EV/Sales Ratio
28.02x
TTM Avg
18.85x
3Y Avg
39.02x
5Y Avg
39.02x
Market Cap
$797.15M
EV/Sales Ratio
6.34x
TTM Avg
5.90x
3Y Avg
8.86x
5Y Avg
33.86x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jade Biosciences, Inc. (JBIO) | $828.30M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $838.73M | 109.69x | 171.82x | 125.82x | 125.82x |
| Beta Bionics, Inc. (BBNX)vs › | $835.48M | 6.70x | 7.73x | 8.84x | 8.84x |
| Ardelyx, Inc. (ARDX)vs › | $821.37M | 2.17x | 3.70x | 6.27x | 11.43x |
| Apnimed, Inc. (APMD)vs › | $802.84M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $803.27M | 1.10x | 1.58x | 2.61x | 5.65x |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $857.04M | 28.02x | 18.85x | 39.02x | 39.02x |
| Gyre Therapeutics, Inc. (GYRE)vs › | $797.15M | 6.34x | 5.90x | 8.86x | 33.86x |
| AdaptHealth Corp. (AHCO)vs › | $787.07M | 0.93x | 1.16x | 1.13x | 1.47x |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $878.74M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
